Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

NCT04733040 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Glomerulonephritis
Membranous Nephropathy
antiPLA2R Positive

Interventions

DRUG: MOR202

Sponsor

HI-Bio, A Biogen Company